^
Association details:
| Biomarker: | GPC3 positive |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | CAR-T immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.
Published date:
05/19/2021
Excerpt:
Eligible patients were aged 18-70 years with histologically confirmed GPC3+ HCC….The duration of remission of one patient with PR is more than 4 months….These initial data provide evidence that G3-CAR-ori2 is safe and holds promising antitumor potential, and supports its continuing development in the treatment of r/r GPC3+HCC.
DOI:
10.1200/JCO.2021.39.15_suppl.4095
